Citius Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$0.89(as of Jan 9, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Citius Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.89
Ticker SymbolCTXR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees23
CountyUSA
Market Cap$18.4M

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc In Our Stock Scanner

As of Jan 12, 2026
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.